OR WAIT null SECS
September 17, 2019
The companies have engaged in a manufacturing scale-up of LTX-03 tablets for clinical testing using LIMITx Technology.
September 16, 2019
The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.
The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.
The companies aim to integrate glucose sensing with insulin delivery technologies to help change the way diabetes is managed.
September 13, 2019
TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.
FDA approved the drug after a successful open-label study of children aged six to 11 years and living with the condition.
The companies will develop and commercialize a Phase III cell therapy candidate for treating chronic low back pain in a deal worth potentially $1 billion.
September 11, 2019
Passage Bio has licensed a sixth gene therapy development program under its partnership with the University of Pennsylvania for the clinical development of a potential treatment for a nerve disorder.
The agency has approved Boehringer Ingelheim’s Ofev (nintedanib), its lung disease drug, for the treatment of patients with systemic sclerosis associated with lung disease.
Xeris Pharmaceuticals has received FDA approval for GVOKE (glucagon), a liquid glucagon for treating hypoglycemia.